Study Finds No Semaglutide Pancreatic Cancer Link in Registry Data

Regulators Review Multicountry Registry Findings

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan reported no link between semaglutide use and pancreatic cancer. Anton Pottegard, a professor at the University of Southern Denmark, presented the findings from nationwide health registries in Denmark, Sweden, and Norway.

The investigation was conducted as an active-comparator, new-user cohort study requested by regulatory agencies as part of the post-authorization safety requirements for semaglutide. Researchers compared new users of semaglutide for type 2 diabetes mellitus (T2DM) against matched new users of non-incretin medications, including sulfonylureas, sodium-glucose cotransporter-2 inhibitors, or insulin.

Eligible patients started their assigned medication and filled at least two prescriptions within the first year of treatment. To avoid protopathic bias, follow-up began one year after patients initiated therapy.

Why Pancreatic Safety Questions Emerged

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for glycemic control in type 2 diabetes mellitus and for weight management. Because glucagon-like peptide-1 receptor agonist medications stimulate pancreatic tissue, scientists previously questioned whether prolonged exposure could alter cellular growth.

The original safety hypothesis stemmed from early adverse event reporting systems and preclinical rodent studies that showed cellular changes in pancreatic tissue. Early clinical case reports also noted occasional episodes of acute pancreatitis, prompting questions about whether chronic background inflammation might elevate long-term cancer risk.

Cancer Rates Proved Similar Across Groups

The analysis tracked 97,464 semaglutide users alongside a balanced cohort of matched comparator patients. The median patient age ranged from 59 to 62 years, and mean follow-up after the one-year lag period spanned 1.40 to 1.85 years.

During follow-up, 131 pancreatic cancer cases occurred among semaglutide users across 167,399 person-years, compared with 123 cases among comparator users across 140,306 person-years. Incidence rates ranged from 0.64 to 0.91 per 1,000 person-years in semaglutide groups and 0.80 to 0.98 per 1,000 person-years in active comparator groups.

Country-specific hazard ratios (HR) showed no elevated risk in Denmark at 1.00 with a 95 percent confidence interval (CI) of 0.66 to 1.51, in Sweden at 0.82 with a 95 percent CI of 0.56 to 1.22, or in Norway at 0.91 with a 95 percent CI of 0.55 to 1.51. The pooled hazard ratio was 0.91 with a 95 percent CI of 0.71 to 1.16, and the pooled incidence rate difference (IRD) was minus 0.10 per 1,000 person-years.

• High-dose semaglutide therapy produced a pooled hazard ratio of 0.74 with a 95 percent confidence interval of 0.40 to 1.40.
• Longer treatment duration showed a pooled hazard ratio of 0.79 with a 95 percent confidence interval of 0.37 to 1.69.
• Extensive sensitivity analyses matched the primary pooled outcome across all three Scandinavian registries.

Study Strengths and Exposure Limitations

The active-comparator, new-user design prevented confounding by comparing semaglutide against other glucose-lowering drugs prescribed at similar stages of type 2 diabetes mellitus. The complete population coverage of Scandinavian national health registries also reduced selection bias.

The average post-lag observation window of 1.40 to 1.85 years captures short-to-medium-term outcomes, but solid tumors often take longer to develop. Patients evaluating individual treatment plans should talk to their clinician about personal risk factors and medication history.